Thomas Dorlo

Professor of Pharmacometrics @UppsalaUni. Fighting against neglected tropical diseases. Chair PAGE SOC. Birder.

[Farmaceutiska fakulteten @FFakulteten]

Achievers of the Week 🥳 The Stanford 2024 Ranking of the world's most cited scientists is official 👉 We congratulate @BergstromLab, @sleep_advocate Christian Benedict, @thomasdorlo and MANY other researchers at our Faculty on the forefront of science ✅ https://t.co/SbrPis4FSv

[Thomas Dorlo @thomasdorlo]

In @JIDJournal we show that people with different forms of #leishmaniasis process treatments very differently.
We can’t just extrapolate visceral leishmaniasis dose regimens to post-kala-azar dermal leishmaniasis (#PKDL) - we need tailored treatments!
https://t.co/L0xKWL9aoS

[PAGE @page_meeting]

📢 The website for the 3⃣2⃣nd PAGE meeting in Rome 🇮🇹 is live: https://t.co/9eGa1RzUaS
📆 Mark your calendars: 26 - 28 June 2024!
✅Don't miss to register from January 22
✍️Abstract submission deadline March 17

[Global Health EDCTP3 @EDCTP3]

#Climatechange will keep having a negative impact on the burden of Neglected Tropical Diseases 🦟

We are happy to annouce that we have committed $24 million for 2024 to tackle NTDs, bringing our investment to $50 million since the Kigali Summit in 2022 🗺️

#RLMForum2023 #Cop28

[Farmaceutiska fakulteten @FFakulteten]

#Achiever of the Week 🚀 Ass. Prof. @thomasdorlo receives a SEK 207,600 grant from the #InDevelop Developing Country Fund to his work to develop a safer & more effective #treatment for #children affected by tropical #skindisease Cutaneous leishmaniasi 👉 https://t.co/AjZV8K0wzy

[Drugs for Neglected Diseases initiative @DNDi]

PKDL is a skin complication that occurs in some people that have been cured of #kalaazar. Patients can face deep societal stigma because of the condition’s characteristic skin lesions.

We need new diagnostic tools & treatments for this debilitating disease. 🔬 #beatNTDs

[Thomas Dorlo @thomasdorlo]

@FFakulteten @UNITE4TB @UlrikaSimonsson @UU_University @elinmasv 👏👏

[Drugs for Neglected Diseases initiative @DNDi]

Children aren’t tiny adults: we can’t necessarily give a lower, weight-based dose, but need to adapt treatments more carefully.

In this study, we evaluated treatment for visceral #leishmaniasis in children and adults in Eastern Africa. @OxfordJournals ➡️https://t.co/BmJnx23AW6

[Thomas Dorlo @thomasdorlo]

@LiavuleMalongo 👏👏 Great job!

[BSAC @BSACandJAC]

In this #OpenAccess review, Chu & Dorlo provide a comprehensive overview of pyronaridine, an older antimalarial now used in artemisinin-based combination therapy:
https://t.co/Y46eMWS3J4
@OUPMedicine @OxfordJournals #JACNews

[Dr Kavita Singh @drskavita]

India is close to eliminating #kalaazar or visceral leishmaniasis, but we are not there yet. We need to address post-kala-azar dermal leishmaniasis (PKDL), a skin condition occurring in 5-10 % people cured of kala-azar that can act as a reservoir of #leishmaniasis infection (1/6)

[Thomas Dorlo @thomasdorlo]

Can we predict the PK of cytotoxic drugs in pregnant women by incorporating gestational changes into existing population PK models? We evaluated this using unique real-world PK data from pregnant women on cancer treatment.
https://t.co/E6XhvnYogZ

[Drugs for Neglected Diseases initiative @DNDi]

Job alert in Brazil! 🇧🇷

🔸 Postdoc positions at @unicampoficial to discover new treatments for tropical parasitic diseases w/ DNDi & @MedsforMalaria: https://t.co/WQ1FBWhSFr

🔸 Senior Drug Safety Manager to oversee our clinical safety activities: https://t.co/tWAFTHnuyN

[Dr. Borna Nyaoke-Anoke @bornanyaoke]

Great opportunity for an #Epidemiologist to join @DNDi as we work to estimate the global burden of #Mycetoma to feed into our R&D work. #NTDs #IkoKazi

https://t.co/Bf2YzrhnYY

[DNDi_Español @DNDi_Espanol]

Nueva herramienta para ayudar a optimizar el tratamiento de la leishmaniasis cutánea y la PKDL: un ensayo fácil, preciso y sensible para medir la anfotericina B liposomal en la piel.

@thomasdorlo @nki_nl @uniutrecht

@sciencedirect 👇https://t.co/bl5LzdveuQ

[Dr. Borna Nyaoke-Anoke @bornanyaoke]

#Sudan conflict has caused a major humanitarian crisis & closure of @MycetomaRC & many other essential healthcare facilities.
#NTDs affect the poorest and political unrest adds another complicated layer in addressing these vulnerable populations. https://t.co/RTQHfA3Mc3

[Thomas Dorlo @thomasdorlo]

@MoniqueWasunna @DNDi @samkariuki2 @KEMRI_Kenya Thank you @MoniqueWasunna for all you have achieved for NTD patients @DNDi Africa. You are a true inspiration!

[PAGE @page_meeting]

With nearly 900 registered participants and 422 submitted abstracts, the record-breaking 3️⃣1️⃣st PAGE meeting has kicked off this morning in A Corūna 🇪🇸!

[Thomas Dorlo @thomasdorlo]

Mycetoma is one of the most neglected tropical diseases. At today's landmark Strategic Plan Expert Meeting initiated by @bornanyaoke and @DNDi we aim to finally resolve this neglect by setting standards for development of new mycetoma treatments.
@FFakulteten @UU_University

[Dr. Borna Nyaoke-Anoke @bornanyaoke]

Landmark moment for the @DNDi #Mycetoma program as over 32 mycetoma experts from 15 countries have come together to work on the Mycetoma Strategic Plan (2023-2028) to develop treatments through design of a target medicine profile driven by patient & health systems needs.

[Drugs for Neglected Diseases initiative @DNDi]

Conflict is a known trigger for outbreaks of neglected tropical diseases, w/ visceral #leishmaniasis epidemics among the deadliest.

This @PLOSNTDs viewpoint warns the global health community of potential epidemics due to the conflict in Northern Ethiopia. https://t.co/RiIxviGaZp